Industry-sponsored clinical trial of GEN 0101 (HVJ-E) in patients with castrate-resistant prostate cancer.
Latest Information Update: 23 Nov 2011
Price :
$35 *
At a glance
- Drugs GEN 0101 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- 23 Nov 2011 New trial record